Brown Advisory
TRML

Brown Advisory’s Tourmaline Bio TRML Stock Holding History

Brown Advisory’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,719
Closed -$635K – 1419
2025
Q2 		$635K Hold
39,719
– – ﹤0.01% 935
2025
Q1 		$604K Hold
39,719
– – ﹤0.01% 938
2024
Q4 		$806K Hold
39,719
– – ﹤0.01% 863
2024
Q3 		$1.02M Buy
+39,719
New +$663K ﹤0.01% 780

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Brown Advisory's TRML Position: Q3 2025 in Review

Brown Advisory sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 39,719 shares — an estimated $635K sold.

Brown Advisory first reported a position in TRML in Q3 2024 and held it in 4 quarters. The position peaked at $1.02M in Q3 2024. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Brown Advisory reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Brown Advisory sold 39,719 Tourmaline Bio shares in Q3 2025, an estimated $635K.
  • Brown Advisory first reported a position in Tourmaline Bio in Q3 2024 and held it in 4 quarters.
  • Brown Advisory's Tourmaline Bio position peaked at $1.02M in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Brown Advisory's 13F filing for Q3 2025, filed 14 Nov 2025.